Previous 10 | Next 10 |
Merck acquires Acceleron for $180 per share in cash. Amicus Therapeutics to launch a genetic medicine company, Caritas Therapeutics through a business combination agreement with ARYA Sciences Acquisition Corp IV. Five9 and Zoom Video Communications mutually terminate their merger ...
Read the full article here. For further details see: Wall Street Breakfast: Buckle Up (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Buckle up U.S. stock index futures are trading down 0.6% following another rough session on Thursday as market closed out September and the third quarter. ...
Proposed 38% Premium Ranks Much Lower Than Average Premium of Approximately 89% for Comparable Biopharma Transactions since 2020 Believes Acceleron Has Significant Momentum Given Recent Positive Data for Sotatercept Drug Candidate Avoro Capital, a long-term and colla...
I will share the history of inhalable medical drugs. Readers will be able to see who has been highly successful in creating and marketing inhalable drugs. I will update my long-term held opinion on Afrezza becoming a viable drug for diabetics. For further details see: Ma...
Merck (NYSE:MRK) CEO Robert Davis said Thursday that its $11.5B purchase of Acceleron (NASDAQ:XLRN) fits into its strategy of making acquisitions that complement its product offerings by adding novel medicines to its portfolio. In an interview with CNBC, Davis also left the door open for futu...
An $11.5B merger deal highlighted Thursday's premarket trading. Confirming recent reports, Merck (NYSE:MRK) signed a deal to acquire Acceleron (NASDAQ:XLRN). In other news, CarMax (NYSE:KMX) lost ground before the bell after its bottom line failed to meet expectations. Kohl's (NYSE:KSS) also ...
A list of 62 recent IPOs debuted on The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 reconstitution. Following up on our previous article on recently-IPOd biotech stocks joining the index, in this article, we discuss another four biotechs ma...
Read the full article here. For further details see: Wall Street Breakfast: Fed Musical Chairs (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Fed musical chairs Two regional Federal Reserve bank presidents are leaving their positions early in the wake of controversy over portfolio holdings. Bosto...
News, Short Squeeze, Breakout and More Instantly...
Acceleron Pharma Inc. Company Name:
XLRN Stock Symbol:
NASDAQ Market:
Acceleron Pharma Inc. Website:
Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Ready to Hel...
In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. However, the big drugmaker recently revealed that it withdrew a key regulatory filing document related to the transaction. In this Motley Fool Live video ...